In the future, efforts should be directed not only toward the production of efficient legumain inhibitors, but also toward the use of legumain for in vivo tumor imaging and therapy, both of which can be targeted in conjunction with legumain to achieve superior therapeutic results. This evidence concerns the gene LGMN and neoplasm.